SHIELD THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.325 GBX | -7.02% |
|
-13.11% | -80.22% |
| Feb. 22 | Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024 | |
| Feb. 21 | FTSE 100 takes hit ahead of FOMC minutes | AN |
| Sales 2023 * | 12.37M 15.42M | Sales 2024 * | 36.3M 45.23M | Capitalization | 10.36M 12.91M |
|---|---|---|---|---|---|
| Net income 2023 * | -27M -33.64M | Net income 2024 * | -10M -12.46M | EV / Sales 2023 * | 1.07 x |
| Net Debt 2023 * | 2.82M 3.52M | Net Debt 2024 * | 16.74M 20.85M | EV / Sales 2024 * | 0.75 x |
| P/E ratio 2023 * |
-0.34
x | P/E ratio 2024 * |
-0.76
x | Employees | 27 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 43.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shield Therapeutics plc
More recommendations
More press releases
| 1 day | -7.02% | ||
| 1 week | -13.11% | ||
| Current month | -34.57% | ||
| 1 month | -39.77% | ||
| 3 months | -79.77% | ||
| 6 months | -78.97% | ||
| Current year | -80.22% |
1 week
1.30
1.50
1 month
1.302.20
Current year
1.307.80
1 year
1.3012.85
3 years
1.3062.60
5 years
1.30202.00
10 years
1.30202.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 18-07-25 | |
| Director/Board Member | 66 | 16-01-31 | |
| Director/Board Member | 57 | 21-05-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.325 | -7.02% | 2,958,047 |
| 24-04-23 | 1.425 | 0.00% | 700,061 |
| 24-04-22 | 1.425 | -3.39% | 705,761 |
| 24-04-19 | 1.475 | 0.00% | 1,069,535 |
| 24-04-18 | 1.475 | -0.34% | 486,264 |
Delayed Quote London S.E., April 24, 2024 at 11:35 am EDT
More quotes
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.
Calendar
2024-04-30
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0132
GBP
Average target price
0.02
GBP
Spread / Average Target
+50.94%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -80.22% | 13.86M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- STX Stock
